Trial Profile

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

23 Jul 2025 According to a Dizal Pharmaceutical media release, data from the trial will be presented at the 2025 World Conference on Lung Cancer (WCLC), taking place in Barcelona, Spain, from September 6 to 9, 2025.
02 Jul 2025 According to a Dizal Pharmaceutical media release, results from this study were recently published in the Journal of Clinical Oncology.
02 Jul 2025 According to a Dizal Pharmaceutical media release, James Chih-Hsin Yang is Co-lead principal investigator of WU-KONG1B.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com